Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Department of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
J Diabetes Investig. 2019 Jan;10(1):171-181. doi: 10.1111/jdi.12859. Epub 2018 Jun 6.
AIMS/INTRODUCTION: Fibroblast growth factor (FGF)19 has been shown to improve glycemic homeostasis and lipid metabolism in animal models. In humans, decreased FGF19 level has been described in diabetes. The present study aimed to investigate the expression of FGF19 in gestational diabetes mellitus (GDM) patients.
Samples for measurement were obtained from 20 women with GDM and 25 healthy controls. The messenger ribonucleic acid (mRNA) and protein expression levels of FGF19, FGF21 and co-receptor β-klotho (KLB) in the placenta, rectus muscle and subcutaneous fat tissues were quantified by real-time quantitative polymerase chain reaction, western blot and immunohistochemistry, respectively.
Women with GDM had significantly lower mRNA and protein expressions of FGF19 than control women in the placenta (mRNA 0.33 ± 0.05 vs 0.72 ± 0.09; protein 0.34 ± 0.13 vs 0.85 ± 0.20) and rectus muscle (mRNA 0.83 ± 0.11 vs 1.28 ± 0.19; protein 0.78 ± 0.24 vs 1.23 ± 0.39). However, there were no significant differences between GDM women and controls with respect to the expression levels of FGF21 and β-klotho in the placenta and rectus muscle. There were almost no detectable FGF19 and FGF21 expressions in subcutaneous fat tissue. Furthermore, β-klotho expression levels were not different between the GDM and control group in subcutaneous fat.
FGF19 expressions are decreased in the placenta and rectus muscle of women with GDM. This might contribute to the pathophysiology or development of GDM.
目的/引言：成纤维细胞生长因子 19（FGF19）已被证明可改善动物模型中的血糖稳态和脂质代谢。在人类中，糖尿病患者的 FGF19 水平降低。本研究旨在探讨妊娠期糖尿病（GDM）患者中 FGF19 的表达情况。
从 20 名 GDM 患者和 25 名健康对照者中获得用于测量的样本。通过实时定量聚合酶链反应、western blot 和免疫组织化学分别定量测定胎盘、腹直肌和皮下脂肪组织中 FGF19、FGF21 和共同受体β-klotho（KLB）的信使核糖核酸（mRNA）和蛋白表达水平。
与对照组相比，GDM 患者的胎盘（mRNA：0.33±0.05 比 0.72±0.09；蛋白：0.34±0.13 比 0.85±0.20）和腹直肌（mRNA：0.83±0.11 比 1.28±0.19；蛋白：0.78±0.24 比 1.23±0.39）中 FGF19 的 mRNA 和蛋白表达水平显著降低。然而，在胎盘和腹直肌中，FGF21 和β-klotho 的表达水平在 GDM 患者与对照组之间无显著差异。在皮下脂肪组织中几乎无法检测到 FGF19 和 FGF21 的表达。此外，在皮下脂肪中，GDM 组和对照组的β-klotho 表达水平无差异。
GDM 患者的胎盘和腹直肌中 FGF19 的表达降低。这可能导致 GDM 的病理生理学或发展。
